SCHEMBL4773088

SCHEMBL4773088

NC(C=O)C(c1ccc(Cl)cc1Cl)N1CCN(Cc2cc(F)ccc2F)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.36
KDM4E B2RXH2 5/20 0.35
MAPT P10636 1/20 0.35
CYP2A13 Q16696 1/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
SOS1 Q07889 1/20 0.34
GRIN2B Q13224 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
CACNA2D1 P54289 1/20 0.33
CACNA1B Q00975 1/20 0.33
CACNB1 Q02641 1/20 0.33
CACNA1C Q13936 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775561 0.89 MAPT (0.43) SIGMAR1MAPTKMT2AMEN1
SCHEMBL4776514 0.84 SIGMAR1 (0.36) SIGMAR1KDM4ECYP2A13ALDH1A1POLB
SCHEMBL4778352 0.80 ALDH1A1 (0.40) SIGMAR1KDM4EMAPTKMT2AALDH1A1
SCHEMBL4773571 0.80 CNR1 (0.48) CACNA2D1CACNA1BCACNB1CACNA1CCNR1
SCHEMBL4776397 0.77 CYP3A4 (0.52) SIGMAR1KDM4EMAPTKMT2AALDH1A1
SCHEMBL4778381 0.75 LSS (0.40) SIGMAR1KMT2AMEN1
SCHEMBL4778576 0.73 FAAH (0.47) KDM4EALDH1A1TDP1LMNA
SCHEMBL4771297 0.71 NPSR1 (0.46) KDM4EMAPTKMT2AALDH1A1POLB
SCHEMBL4773085 0.70 HDAC8 (0.55)
SCHEMBL4772508 0.69 CYP3A4 (0.36) CACNA2D1CACNA1BCACNB1CACNA1CCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996550-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES Novartis AG (CH) 2008-12-03 EP disclosed
WO-2007038459-A2 CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES NOVARTIS AG (CH) 2007-04-05 WO disclosed